Table 2. Selected tumor characteristics.

	Group A(3-weekly)	Group B(weekly)
	N (%)	N (%)
ER status (n = 62)
Positive	29 (91)	24 (80)
Negative	3 (9)	6 (20)
PgR status (n = 60)
Positive	24 (75)	17 (61)
Negative	8 (25)	11 (39)
HER2 (n = 61)
Positive	5 (16)	2 (7)
Negative	26 (84)	28 (93)
Ki67 (n = 62)
Positive (High: ≥14%)	24 (75)	22 (73)
Negative (Low: <14%)	8 (25)	8 (27)
Histological grade
1	2 (6)	2 (6)
2	13 (41)	17 (53)
3	15 (47)	12 (38)
Unknown	2 (6)	1 (3)
Triple-negative patients (n = 59; A = 31 and B = 28)	1 (3)	5 (18)
Metastatic sites
Locoregional	14 (44)	9 (28)
Nodes	17 (53)	9 (28)
Skin	3 (9)	0 (0)
Residual breast	2 (6)	0 (0)
Soft tissue	4 (12)	3 (9)
Distant	31 (97)	32 (100)
Bones	14 (44)	18 (56)
Lung/pleura	22 (69)	22 (69)
Liver	17 (53)	16 (50)
Brain	1 (3)	1 (3)
Soft tissue	17 (56)	23 (72)
Other breast	0 (0)	1 (3)
Visceral metastases	26 (81.3%)	27 (84.4%)
Multiple metastases
1–3	24 (75)	23 (72)
>3	8 (25)	9 (28)